Key Insights

Highlights

Success Rate

67% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

12.5%

1 terminated out of 8 trials

Success Rate

66.7%

-19.8% vs benchmark

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed with results

Key Signals

2 with results67% success

Data Visualizations

Phase Distribution

8Total

Not Applicable (1)

P 1 (4)

P 2 (2)

P 4 (1)

Trial Status

Completed2

Unknown2

Withdrawn2

Recruiting1

Terminated1

Trial Success Rate

66.7%

Benchmark: 86.5%

Based on 2 completed trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT07295951Phase 1Recruiting

A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia

NCT05521087Phase 1WithdrawnPrimary

A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias

NCT02141828Phase 1Completed

A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene

NCT02145039Not ApplicableTerminatedPrimary

Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases

NCT01479582Phase 2Withdrawn

Providing Access to Cord Blood Units for Transplants

NCT01826214Phase 2CompletedPrimary

Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia

NCT01919866Phase 1UnknownPrimary

Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells

NCT01339988Phase 4UnknownPrimary

Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)

Showing all 8 trials